Found: 1
Select item for more details and to access through your institution.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2023, doi. 10.1007/s00277-020-04357-z
- By:
- Publication type:
- Article